At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 36 enrolled
Drug / intervention
etoricoxib +1 moredrug
Likely dose
etoricoxib 120 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Randomized, 2-Period, Single-Dose, Balanced, Crossover Study in Healthy Subjects to Establish the Bioequivalence of the 20% and 30% Etoricoxib (MK0663) Formulations
In Brief
A Phase 1 clinical trial evaluating etoricoxib and Comparator: etoricoxib for Pain. Completed, enrolled 36 participants.
Detailed Summary
This study will establish the bioequivalence of the 20%, milled, roller compaction final market image (FMI) etoricoxib tablets and 30% unmilled, roller compaction (UMC) etoricoxib tablets.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPain
Countries--
Collaborators--
Timeline
Phase 1CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2002
Primary CompletionDec 2002
First PostedJul 2009
TodayJul 2026
First PostedJul 23, 2009
Enrollment StartNov 1, 2002
Primary CompletionDec 1, 2002
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 16.9 years ago
Interventions
etoricoxibdrug
Single dose etoricoxib 120 mg 20% final market image tablet in one of two treatment periods.
Comparator: etoricoxibdrug
Single dose etoricoxib 120 mg 30% unmilled, roller compaction tablet in one of two treatment periods.